Exact Mass: 287.19573

Exact Mass Matches: 287.19573

Found 425 metabolites which its exact mass value is equals to given mass value 287.19573, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Galantamine

(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol

C17H21NO3 (287.1521356)


Galanthamine is a benzazepine alkaloid isolated from certain species of daffodils. It has a role as an antidote to curare poisoning, an EC 3.1.1.7 (acetylcholinesterase) inhibitor, a cholinergic drug, an EC 3.1.1.8 (cholinesterase) inhibitor and a plant metabolite. It is an organic heterotetracyclic compound, a tertiary amino compound, a benzazepine alkaloid and a benzazepine alkaloid fundamental parent. It is a conjugate base of a galanthamine(1+). Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimers disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as Galanthus nivalis. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade. Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and synthesis. Galantamine blocks the breakdown of acetylcholine in the synaptic cleft, thereby increasing acetylcholine neurotransmission. It also acts as an allosteric modulator of the nicotinic receptor, giving its dual mechanism of action clinical significance. The drug was approved by the FDA in 2001 for the treatment of mild to moderate dementia of the Alzheimers type. As Alzheimers disease is a progressive neurodegenerative disorder, galantamine is not known to alter the course of the underlying dementing process. Galantamine works to block the enzyme responsible for the breakdown of acetylcholine in the synaptic cleft, thereby enhancing cholinergic neuron function and signalling. Under this hypothesized mechanism of action, the therapeutic effects of galantamine may decrease as the disease progression advances and fewer cholinergic neurons remain functionally intact. It is therefore not considered to be a disease-modifying drug. Galantamine is marketed under the brand name Razadyne, and is available as oral immediate- and extended-release tablets and solution. Galantamine is a Cholinesterase Inhibitor. The mechanism of action of galantamine is as a Cholinesterase Inhibitor. Galantamine is an oral acetylcholinesterase inhibitor used for therapy of Alzheimer disease. Galantamine is associated with a minimal rate of serum enzyme elevations during therapy and has not been implicated as a cause of clinically apparent liver injury. Galantamine is a natural product found in Pancratium trianthum, Lycoris sanguinea, and other organisms with data available. A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. See also: Galantamine Hydrobromide (active moiety of). A benzazepine derived from norbelladine. It is found in galanthus and other amaryllidaceae. Galantamine is a cholinesterase inhibitor that has been used to reverse the muscular effects of gallamine triethiodide and tubocurarine, and has been studied as a treatment for Alzheimers disease and other central nervous system disorders. [PubChem] D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010277 - Parasympathomimetics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors N - Nervous system > N06 - Psychoanaleptics > N06D - Anti-dementia drugs > N06DA - Anticholinesterases D002491 - Central Nervous System Agents > D018697 - Nootropic Agents A benzazepine alkaloid isolated from certain species of daffodils. C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM. Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM.

   

Mesembrenone

6H-Indol-6-one, 3a-(3,4-dimethoxyphenyl)-1,2,3,3a,7,7a-hexahydro-1-methyl-, (3aR-cis)-

C17H21NO3 (287.1521356)


Mesembrenone is a member of pyrrolidines. Mesembrenone is a natural product found in Bergeranthus scapiger, Oscularia deltoides, and other organisms with data available.

   

Etodolac

(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid

C17H21NO3 (287.1521356)


Etodolac is only found in individuals that have used or taken this drug. It is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Similar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5 – 50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss. M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AB - Acetic acid derivatives and related substances D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors D004791 - Enzyme Inhibitors > D016861 - Cyclooxygenase Inhibitors > D052246 - Cyclooxygenase 2 Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D006133 - Growth Substances > D010937 - Plant Growth Regulators > D007210 - Indoleacetic Acids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents KEIO_ID E034; [MS2] KO008956 KEIO_ID E034

   

Cyproheptadine

1-methyl-4-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}piperidine

C21H21N (287.16739060000003)


Cyproheptadine is only found in individuals that have used or taken this drug. It is a serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. [PubChem]Cyproheptadine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadines ability to stimulate appetite. R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D003879 - Dermatologic Agents > D000982 - Antipruritics D005765 - Gastrointestinal Agents D018926 - Anti-Allergic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders[1][2].

   

Procyclidine

1-cyclohexyl-1-phenyl-3-(pyrrolidin-1-yl)propan-1-ol

C19H29NO (287.2249024)


Procyclidine is only found in individuals that have used or taken this drug. It is a muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. [PubChem]The mechanism of action is unknown. It is thought that Procyclidine acts by blocking central cholinergic receptors, and thus balancing cholinergic and dopaminergic activity in the basal ganglia. Many of its effects are due to its pharmacologic similarities with atropine. Procyclidine exerts an antispasmodic effect on smooth muscle, and may produce mydriasis and reduction in salivation. D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

Dihydromorphine

(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-triene-10,14-diol

C17H21NO3 (287.1521356)


Dihydromorphine is a metabolite of Hydromorphone. Dihydromorphine is a semi-synthetic opioid structurally related to and derived from morphine. The 7,8-double bond in morphine is reduced to a single bond to get dihydromorphine. (Wikipedia) D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Naftifine

N-methyl-N-(1-naphthalenylmethyl)-3-phenyl-2-propen-1-amine

C21H21N (287.16739060000003)


Naftifine is only found in individuals that have used or taken this drug. It is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.Although the exact mechanism of action against fungi is not known, naftifine appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2,3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells. D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

   

Ritodrine

4-(2-{[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)phenol

C17H21NO3 (287.1521356)


Ritodrine is only found in individuals that have used or taken this drug. It is an adrenergic beta-agonist used to control premature labor. [PubChem]Ritodrine is beta-2 adrenergic agonist. It binds to beta-2 adrenergic receptors on outer membrane of myometrial cell, activates adenyl cyclase to increase the level of cAMP which decreases intracellular calcium and leads to a decrease of uterine contractions. G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents

   

Zolmitriptan

(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one

C16H21N3O2 (287.1633686)


Zolmitriptan is only found in individuals that have used or taken this drug. It is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water. [Wikipedia]Zolmitriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations > N02CC - Selective serotonin (5ht1) agonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D000890 - Anti-Infective Agents > D023303 - Oxazolidinones

   

Octanoylcarnitine

O-octanoyl-R-carnitine

C15H29NO4 (287.2096474)


CONFIDENCE standard compound; INTERNAL_ID 253 L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer[1][2][3].

   
   

NAc-AAA-ME

Methyl-N-acetyl-N-L-alanyl-N-L-alanyl alaninate

C12H21N3O5 (287.1481136)


   
   

4-aminoestra-1(10),2,4-triene-3,17-diol

4-Aminoestra-1,3,5(10)-triene-3,17beta-diol

C18H25NO2 (287.188519)


   

2-Aminoestradiol

2-Aminoestra-1,3,5(10)-triene-3,17beta-diol; 2-Aminoestradiol

C18H25NO2 (287.188519)


   

Piperanine

(2E)-5-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)pent-2-en-1-one

C17H21NO3 (287.1521356)


Isolated from pepper. Piperanine is found in herbs and spices and pepper (spice). Piperanine is found in herbs and spices. Piperanine is isolated from pepper.

   

Feruperine

(2E,4Z)-5-(4-hydroxy-3-methoxyphenyl)-1-(piperidin-1-yl)penta-2,4-dien-1-one

C17H21NO3 (287.1521356)


Alkaloid from pepper (Piper nigrum) (Piperaceae). Feruperine is found in herbs and spices and pepper (spice). Feruperine is found in herbs and spices. Feruperine is an alkaloid from pepper (Piper nigrum) (Piperaceae).

   

Arginylleucine

(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C12H25N5O3 (287.19573)


Arginylleucine is a dipeptide composed of arginine and leucine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

N-[2-(4-Prenyloxyphenyl)ethyl]tiglamide

(2E)-2-Methyl-N-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidate

C18H25NO2 (287.188519)


N-[2-(4-Prenyloxyphenyl)ethyl]tiglamide is a constituent of Boronia megastigma (brown boronia). Constituent of Boronia megastigma (brown boronia)

   

Leucyl-Arginine

2-[(2-Amino-1-hydroxy-4-methylpentylidene)amino]-5-carbamimidamidopentanoate

C12H25N5O3 (287.19573)


Leucyl-Arginine is a dipeptide composed of leucine and arginine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Arginylisoleucine

(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C12H25N5O3 (287.19573)


Arginylisoleucine is a dipeptide composed of arginine and isoleucine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Isoleucyl-Arginine

2-[(2-Amino-1-hydroxy-3-methylpentylidene)amino]-5-carbamimidamidopentanoate

C12H25N5O3 (287.19573)


Isoleucyl-Arginine is a dipeptide composed of isoleucine and arginine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Cycrimine

1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol

C19H29NO (287.2249024)


Cycrimine is only found in individuals that have used or taken this drug. It is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinsons disease. Cycrimine binds the muscarinic acetylcholine receptor M1, effectively inhibiting acetylcholine. This decrease in acetylcholine restores the normal dopamine-acetylcholine balance and relieves the symptoms of Parkinsons disease. C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder[1][2][3][4].

   

Arginylhydroxyproline

(2S,4R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]-4-hydroxypyrrolidine-2-carboxylic acid

C11H21N5O4 (287.15934660000005)


Arginylhydroxyproline is a dipeptide composed of arginine and hydroxyproline. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Hydroxyprolyl-Arginine

5-Carbamimidamido-2-{[hydroxy(4-hydroxypyrrolidin-2-yl)methylidene]amino}pentanoate

C11H21N5O4 (287.15934660000005)


Hydroxyprolyl-Arginine is a dipeptide composed of hydroxyproline and arginine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Nordihydrocodeine

(1S,5R,14S)-10-methoxy-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-ol

C17H21NO3 (287.1521356)


Nordihydrocodeine belongs to the family of Morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.

   

6alpha-Hydroxy-hydromorphone

(14S)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-triene-10,14-diol

C17H21NO3 (287.1521356)


6alpha-Hydroxy-hydromorphone is a metabolite of hydromorphone. Hydromorphone, a more common synonym for dihydromorphinone, commonly a hydrochloride (brand names Palladone, Dilaudid, and numerous others) is a very potent centrally acting analgesic drug of the opioid class. It is a derivative of morphine, to be specific, a hydrogenated ketone thereof and, therefore, a semi-synthetic drug. It is, in medical terms, an opioid analgesic and, in legal terms, a narcotic. (Wikipedia)

   

6beta-Hydroxy-hydromorphone

(14R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-triene-10,14-diol

C17H21NO3 (287.1521356)


6beta-Hydroxy-hydromorphone is a metabolite of hydromorphone. Hydromorphone, a more common synonym for dihydromorphinone, commonly a hydrochloride (brand names Palladone, Dilaudid, and numerous others) is a very potent centrally acting analgesic drug of the opioid class. It is a derivative of morphine, to be specific, a hydrogenated ketone thereof and, therefore, a semi-synthetic drug. It is, in medical terms, an opioid analgesic and, in legal terms, a narcotic. (Wikipedia)

   

Dihydroisomorphine

(1S,5R,13R,14R,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-triene-10,14-diol

C17H21NO3 (287.1521356)


Dihydroisomorphine is a metabolite of hydromorphone. Hydromorphone, a more common synonym for dihydromorphinone, commonly a hydrochloride (brand names Palladone, Dilaudid, and numerous others) is a very potent centrally acting analgesic drug of the opioid class. It is a derivative of morphine, to be specific, a hydrogenated ketone thereof and, therefore, a semi-synthetic drug. It is, in medical terms, an opioid analgesic and, in legal terms, a narcotic. (Wikipedia)

   

3-Methylheptanoylcarnitine

3-[(3-methylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO4 (287.2096474)


3-Methylheptanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methylheptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methylheptanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Methylheptanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methylheptanoylcarnitine

3-[(4-methylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO4 (287.2096474)


4-Methylheptanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methylheptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methylheptanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Methylheptanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Methylheptanoylcarnitine

3-[(6-methylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO4 (287.2096474)


6-Methylheptanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methylheptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methylheptanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Methylheptanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Methylheptanoylcarnitine

3-[(5-methylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO4 (287.2096474)


5-Methylheptanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methylheptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methylheptanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Methylheptanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxyhept-4-enoylcarnitine

3-[(3-hydroxyhept-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO5 (287.173264)


3-hydroxyhept-4-enoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyhept-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxyhept-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyhept-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5E)-3-Hydroxyhept-5-enoylcarnitine

3-[(3-hydroxyhept-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO5 (287.173264)


(5E)-3-hydroxyhept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5E)-3-hydroxyhept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E)-3-hydroxyhept-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5E)-3-hydroxyhept-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyhept-5-enoylcarnitine

3-[(2-hydroxyhept-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO5 (287.173264)


2-hydroxyhept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyhept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-hydroxyhept-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-hydroxyhept-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Oxoheptanoylcarnitine

3-[(3-oxoheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO5 (287.173264)


3-Oxoheptanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxoheptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Oxoheptanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Oxoheptanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Lauroyl Serine

2-dodecanamido-3-hydroxypropanoic acid

C15H29NO4 (287.2096474)


N-lauroyl serine, also known as N-dodecanoyl-ser belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Serine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Serine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Serine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(4R)-4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one

4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one

C16H21N3O2 (287.1633686)


   

Ritodrina

4-(1-hydroxy-2-{[2-(4-hydroxyphenyl)ethyl]amino}propyl)phenol

C17H21NO3 (287.1521356)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents

   

(2S)-1-[2-(2-Adamantylamino)acetyl]pyrrolidine-2-carbonitrile

1-{2-[(adamantan-2-yl)amino]acetyl}pyrrolidine-2-carbonitrile

C17H25N3O (287.199752)


   

Cyanopindolol

4-[3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile

C16H21N3O2 (287.1633686)


D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists

   

Dipropyl-5-CT

3-[2-(Dipropylamino)ethyl]-1H-indole-5-carboximidate

C17H25N3O (287.199752)


   

Hydromorphine

4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-triene-10,14-diol

C17H21NO3 (287.1521356)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Epigalanthamin

9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraen-14-ol

C17H21NO3 (287.1521356)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010277 - Parasympathomimetics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D002491 - Central Nervous System Agents > D018697 - Nootropic Agents D004791 - Enzyme Inhibitors

   
   

Valproylcarnitine

3-[(2-Propylpentanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C15H29NO4 (287.2096474)


   

Thesinine

(Hexahydro-1H-pyrrolizin-1-yl)methyl (2E)-3-(4-hydroxyphenyl)prop-2-enoic acid

C17H21NO3 (287.1521356)


Thesinine is a member of the class of compounds known as coumaric acid esters. Coumaric acid esters are aromatic compounds containing an ester derivative of coumaric acid. Thesinine is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Thesinine can be found in borage, which makes thesinine a potential biomarker for the consumption of this food product. Thesinine is a pyrrolizidine alkaloid first isolated from Thesium minkwitzianum from which it derives its name. It is also found in the flowers and seeds of borage .

   

(-)-N-(2-Oxopyrrolidinomethyl)cytisine

(-)-N-(2-Oxopyrrolidinomethyl)cytisine

C16H21N3O2 (287.1633686)


   
   
   

O-Methylglycosolone

4,8-Dimethoxy-1-methyl-3-prenylquinolin-2-one

C17H21NO3 (287.1521356)


   
   

Latisodine

4-[2-[(3,4-dimethoxyphenyl)methylamino]ethyl]phenol

C17H21NO3 (287.1521356)


   

Pluviine

O-Methylnorpluviine

C17H21NO3 (287.1521356)


   
   

Malatyamine ethylester

Malatyamine ethylester

C17H21NO3 (287.1521356)


   

2-NONYL-4-HYDROXYQUINOLINE N-OXIDE

2-NONYL-4-HYDROXYQUINOLINE N-OXIDE

C18H25NO2 (287.188519)


   
   
   
   

Tribenzylamine

Tribenzylamine

C21H21N (287.16739060000003)


CONFIDENCE standard compound; INTERNAL_ID 1132; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8039; ORIGINAL_PRECURSOR_SCAN_NO 8037 CONFIDENCE standard compound; INTERNAL_ID 1132; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8040; ORIGINAL_PRECURSOR_SCAN_NO 8038 CONFIDENCE standard compound; INTERNAL_ID 1132; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8054; ORIGINAL_PRECURSOR_SCAN_NO 8052 CONFIDENCE standard compound; INTERNAL_ID 1132; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8082; ORIGINAL_PRECURSOR_SCAN_NO 8080 CONFIDENCE standard compound; INTERNAL_ID 1132; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8101; ORIGINAL_PRECURSOR_SCAN_NO 8100 CONFIDENCE standard compound; INTERNAL_ID 1132; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8147; ORIGINAL_PRECURSOR_SCAN_NO 8146 CONFIDENCE standard compound; INTERNAL_ID 8376

   

(4-oxido-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-4-ium-1-yl)methyl 2,3-dihydroxy-3-methylpentanoate

(4-oxido-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-4-ium-1-yl)methyl 2,3-dihydroxy-3-methylpentanoate

C14H25NO5 (287.173264)


   
   
   

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methyl-2-methylpropanamide

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methyl-2-methylpropanamide

C18H25NO2 (287.188519)


   

(-)-8-norindolactam V|(-)-des-N-methylindolactam-V|(-)-N13-desmethylindolactam V|(-)-N13-desmethylindolactam-V|des-methyl-(-)-indolactam V|des-N-methylindolactam V|desmethyl indolactam V

(-)-8-norindolactam V|(-)-des-N-methylindolactam-V|(-)-N13-desmethylindolactam V|(-)-N13-desmethylindolactam-V|des-methyl-(-)-indolactam V|des-N-methylindolactam V|desmethyl indolactam V

C16H21N3O2 (287.1633686)


   

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-3-methylbutanamide

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-3-methylbutanamide

C18H25NO2 (287.188519)


   
   
   
   

5t-benzo[1,3]dioxol-5-yl-penta-2t,4-dienoic acid isopentylamide|5t-Benzo[1,3]dioxol-5-yl-penta-2t,4-diensaeure-isopentylamid|piperic acid isopentyl amide

5t-benzo[1,3]dioxol-5-yl-penta-2t,4-dienoic acid isopentylamide|5t-Benzo[1,3]dioxol-5-yl-penta-2t,4-diensaeure-isopentylamid|piperic acid isopentyl amide

C17H21NO3 (287.1521356)


   
   
   

8-Aza-D-homo-oestradiol

8-Aza-D-homo-oestradiol

C18H25NO2 (287.188519)


   

(2S)-3-(2,3-Dihydroxy-3-methylbutyl)-6-(3-methyl-2-butenyl)indole|3-Methyl-1-[6-(3-methyl-2-butenyl)-1H-indol-3-yl]-2,3-butanediol

(2S)-3-(2,3-Dihydroxy-3-methylbutyl)-6-(3-methyl-2-butenyl)indole|3-Methyl-1-[6-(3-methyl-2-butenyl)-1H-indol-3-yl]-2,3-butanediol

C18H25NO2 (287.188519)


   
   

l-Rotundin, l-Tetrahydropalmatine|Rotundin

l-Rotundin, l-Tetrahydropalmatine|Rotundin

C17H21NO3 (287.1521356)


   

3-O-methylepimacowine

3-O-methylepimacowine

C17H21NO3 (287.1521356)


   

(n-Nonanol-9)-2-chinolon-4|2-(9-hydroxy-nonyl)-1H-quinolin-4-one

(n-Nonanol-9)-2-chinolon-4|2-(9-hydroxy-nonyl)-1H-quinolin-4-one

C18H25NO2 (287.188519)


   

bisdehydroneostemoninine

bisdehydroneostemoninine

C17H21NO3 (287.1521356)


   

1-Methyl-8-methoxy-2-heptylquinolin-4(1H)-one

1-Methyl-8-methoxy-2-heptylquinolin-4(1H)-one

C18H25NO2 (287.188519)


   

(2R)-3-(1,3-Dihydroxy-3-methylbut-2-yl)-6-(3-methyl-2-butenyl)indole|3-Methyl-2-[6-(3-methyl-2-butenyl)-1H-indol-3-yl]-1,3-butanediol

(2R)-3-(1,3-Dihydroxy-3-methylbut-2-yl)-6-(3-methyl-2-butenyl)indole|3-Methyl-2-[6-(3-methyl-2-butenyl)-1H-indol-3-yl]-1,3-butanediol

C18H25NO2 (287.188519)


   

7-[4-(dimethylamino)phenyl]-4,6-dimethyl-7-oxohepta-2,4-dienoic acid

7-[4-(dimethylamino)phenyl]-4,6-dimethyl-7-oxohepta-2,4-dienoic acid

C17H21NO3 (287.1521356)


   

1-3-guanidinopropyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline

1-3-guanidinopropyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline

C15H21N5O (287.1746016)


   

(E,E)-N-(4-Hydroxyphenethyl)-2,4-decadienamide

(E,E)-N-(4-Hydroxyphenethyl)-2,4-decadienamide

C18H25NO2 (287.188519)


   

3alpha-cynnamoyloxytropan-6beta-ol

3alpha-cynnamoyloxytropan-6beta-ol

C17H21NO3 (287.1521356)


   
   

(E,E)-2,4-decadienoic acid p-hydroxyphenethylamide|Deca-2t,4t-diensaeure-(4-hydroxyphenyl-aethyl)-amid

(E,E)-2,4-decadienoic acid p-hydroxyphenethylamide|Deca-2t,4t-diensaeure-(4-hydroxyphenyl-aethyl)-amid

C18H25NO2 (287.188519)


   
   
   
   
   
   
   
   
   
   
   
   
   
   

2-Undecyl-thiazolidine-4-carboxylic acid

2-Undecyl-thiazolidine-4-carboxylic acid

C15H29NO2S (287.19188940000004)


   

4-(2-(3,4-Dimethoxybenzylamino)ethyl)phenol

4-(2-(3,4-Dimethoxybenzylamino)ethyl)phenol

C17H21NO3 (287.1521356)


   
   

Epigalantamine

(1S,12S,14S)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0?,??.0?,??]heptadeca-6(17),7,9,15-tetraen-14-ol

C17H21NO3 (287.1521356)


Epigalantamine is a natural product found in Lycoris sanguinea, Lycoris radiata, and other organisms with data available.

   

etodolac

etodolac

C17H21NO3 (287.1521356)


M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AB - Acetic acid derivatives and related substances D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors D004791 - Enzyme Inhibitors > D016861 - Cyclooxygenase Inhibitors > D052246 - Cyclooxygenase 2 Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D006133 - Growth Substances > D010937 - Plant Growth Regulators > D007210 - Indoleacetic Acids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3308

   

naftifine

naftifine

C21H21N (287.16739060000003)


D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent CONFIDENCE standard compound; EAWAG_UCHEM_ID 3581

   

Galantamine

(-)Galanthamine

C17H21NO3 (287.1521356)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010277 - Parasympathomimetics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors N - Nervous system > N06 - Psychoanaleptics > N06D - Anti-dementia drugs > N06DA - Anticholinesterases Origin: Plant; SubCategory_DNP: Isoquinoline alkaloids, Amaryllidaceae alkaloids D002491 - Central Nervous System Agents > D018697 - Nootropic Agents C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors Origin: Plant, Benzazepines CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 27 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.263 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.257 Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM. Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM.

   
   

Zolmitriptan

Zolmitriptan (Zomig)

C16H21N3O2 (287.1633686)


N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations > N02CC - Selective serotonin (5ht1) agonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D000890 - Anti-Infective Agents > D023303 - Oxazolidinones

   

(E)-5-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylpent-2-en-1-one

NCGC00180838-02!(E)-5-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylpent-2-en-1-one

C17H21NO3 (287.1521356)


   

C17H21NO3_3a-(3,4-Dimethoxyphenyl)-1-methyl-1,2,3,3a,4,5-hexahydro-6H-indol-6-one

NCGC00385278-01_C17H21NO3_3a-(3,4-Dimethoxyphenyl)-1-methyl-1,2,3,3a,4,5-hexahydro-6H-indol-6-one

C17H21NO3 (287.1521356)


   

L-Octanoylcarnitine

(3R)-3-(octanoyloxy)-4-(trimethylazaniumyl)butanoate

C15H29NO4 (287.2096474)


L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer[1][2][3].

   

CYPROHEPTADINE

CYPROHEPTADINE

C21H21N (287.16739060000003)


R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D003879 - Dermatologic Agents > D000982 - Antipruritics D005765 - Gastrointestinal Agents D018926 - Anti-Allergic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders[1][2].

   
   

Piperanine

(2E)-5-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)pent-2-en-1-one

C17H21NO3 (287.1521356)


   

3a-(3,4-dimethoxyphenyl)-1-methyl-2,3,4,5-tetrahydroindol-6-one

3a-(3,4-dimethoxyphenyl)-1-methyl-2,3,4,5-tetrahydroindol-6-one

C17H21NO3 (287.1521356)


   

4-O,N-dimethylnorbelladine

4-O,N-dimethylnorbelladine

C17H21NO3 (287.1521356)


   
   

Octanoyl-carnitine; AIF; CE10; CorrDec

Octanoyl-carnitine; AIF; CE10; CorrDec

C15H29NO4 (287.2096474)


   

Octanoyl-carnitine; AIF; CE30; CorrDec

Octanoyl-carnitine; AIF; CE30; CorrDec

C15H29NO4 (287.2096474)


   

Octanoyl-carnitine; AIF; CE0; MS2Dec

Octanoyl-carnitine; AIF; CE0; MS2Dec

C15H29NO4 (287.2096474)


   

Octanoyl-carnitine; AIF; CE10; MS2Dec

Octanoyl-carnitine; AIF; CE10; MS2Dec

C15H29NO4 (287.2096474)


   

Octanoyl-carnitine; AIF; CE30; MS2Dec

Octanoyl-carnitine; AIF; CE30; MS2Dec

C15H29NO4 (287.2096474)


   
   
   

GALANTHAMINE_77.1\\%

GALANTHAMINE_77.1\\%

C17H21NO3 (287.1521356)


   
   

GALANTHAMINE_53.1\\%

GALANTHAMINE_53.1\\%

C17H21NO3 (287.1521356)


   

PQS-C9 and NQNO mixture, 2-nonyl-3-hydroxy 4(1H)-quinolone

PQS-C9 and NQNO mixture, 2-nonyl-3-hydroxy 4(1H)-quinolone

C18H25NO2 (287.188519)


   
   
   
   
   
   
   
   
   

Nordihydrocodeine

(9-methoxy-3-trimethylsilyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-yl)oxy-trimethylsilane

C17H21NO3 (287.1521356)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids

   
   
   
   
   
   

(2S,6R,7S,8S)-7-((E)-buta-1,3-dien-1-yl)-2-(penta-3,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

(2S,6R,7S,8S)-7-((E)-buta-1,3-dien-1-yl)-2-(penta-3,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

C19H29NO (287.2249024)


   

(2S,6R,7S,8S)-7-((E)-buta-1,3-dien-1-yl)-2-((E)-penta-2,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

(2S,6R,7S,8S)-7-((E)-buta-1,3-dien-1-yl)-2-((E)-penta-2,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

C19H29NO (287.2249024)


   

(2R,6R,7S,8S)-7-((E)-buta-1,3-dien-1-yl)-2-(pent-4-yn-1-yl)-1-azaspiro[5.5]undecan-8-ol

(2R,6R,7S,8S)-7-((E)-buta-1,3-dien-1-yl)-2-(pent-4-yn-1-yl)-1-azaspiro[5.5]undecan-8-ol

C19H29NO (287.2249024)


   

2-((1S,3aS,6S)-6-((E)-pent-2-en-4-yn-1-yl)dodecahydropyrrolo[1,2-a]quinolin-1-yl)ethan-1-ol

2-((1S,3aS,6S)-6-((E)-pent-2-en-4-yn-1-yl)dodecahydropyrrolo[1,2-a]quinolin-1-yl)ethan-1-ol

C19H29NO (287.2249024)


   

2-Undecyl-thiazolidine-4-carboxylic acid

2-Undecyl-thiazolidine-4-carboxylic acid

C15H29NO2S (287.19188940000004)


   

CAY10434

6-[4-(1H-imidazol-1-yl)phenoxy]-N,N-dimethyl-1-hexanamine

C17H25N3O (287.199752)


   

CAY10462

6-[4-(1H-imidazol-1-yl)phenoxy]-N,N-dimethyl-1-hexanamine, dihydrochloride

C17H25N3O (287.199752)


   

(±)-Octanoylcarnitine

(±)-Octanoylcarnitine

C15H29NO4 (287.2096474)


   

cycrimine

1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol

C19H29NO (287.2249024)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder[1][2][3][4].

   

Arg-hpro

5-carbamimidamido-2-[(4-hydroxypyrrolidin-2-yl)formamido]pentanoic acid

C11H21N5O4 (287.15934660000005)


   

Arg-ile

2-(2-amino-3-methylpentanamido)-5-carbamimidamidopentanoic acid

C12H25N5O3 (287.19573)


A dipeptide formed from L-arginyl and L-isoleucine residues.

   

Arg-leu

2-(2-amino-4-methylpentanamido)-5-carbamimidamidopentanoic acid

C12H25N5O3 (287.19573)


A dipeptide formed from L-arginyl and L-leucine residues.

   

Hpro-arg

1-(2-amino-5-carbamimidamidopentanoyl)-4-hydroxypyrrolidine-2-carboxylic acid

C11H21N5O4 (287.15934660000005)


   

Ile-arg

2-(2-amino-5-carbamimidamidopentanamido)-3-methylpentanoic acid

C12H25N5O3 (287.19573)


A dipeptide formed from L-isoleucine and L-arginine residues.

   

Leu-arg

2-(2-amino-5-carbamimidamidopentanamido)-4-methylpentanoic acid

C12H25N5O3 (287.19573)


A dipeptide composed of L-leucine and L-arginine joined by peptide linkages.

   

Feruperine

(2E,4Z)-5-(4-hydroxy-3-methoxyphenyl)-1-(piperidin-1-yl)penta-2,4-dien-1-one

C17H21NO3 (287.1521356)


   

N-[2-(4-Prenyloxyphenyl)ethyl]tiglamide

(2E)-2-methyl-N-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enamide

C18H25NO2 (287.188519)


   

CAR 8:0

3-(octanoyloxy)-4-(trimethylammonio)butanoate;octanoylcarnitine

C15H29NO4 (287.2096474)


   

NA 18:6;O

Deca-2E,4E-dienoic acid 4-hydroxy-2-phenylethylamide

C18H25NO2 (287.188519)


   

Octanoylcarnitine (C8)

(3R)-3-(octanoyloxy)-4-(trimethylazaniumyl)butanoate

C15H29NO4 (287.2096474)


L-Octanoylcarnitine is the physiologically active form of octanoylcarnitine (PMID: 11274033). Octanoylcarnitine is detected in medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. MCAD is characterized by an intolerance to prolonged fasting, recurrent episodes of hypoglycemic coma with medium-chain dicarboxylic aciduria, impaired ketogenesis, and low plasma and tissue carnitine levels (OMIM: 201450). L-Octanoylcarnitine is also found to be associated with celiac disease and glutaric aciduria II, which are inborn errors of metabolism. L-Octanoylcarnitine is the physiologically active form of octanoylcarnitine. (PMID 11274033) L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer[1][2][3].

   

7-Dibutylamino-4-methyl coumarin

7-Dibutylamino-4-methyl coumarin

C18H25NO2 (287.188519)


   

tert-butyl 4-(4-cyanophenyl)piperazine-1-carboxylate

tert-butyl 4-(4-cyanophenyl)piperazine-1-carboxylate

C16H21N3O2 (287.1633686)


   

4-tert-butyl-2-[3-(trifluoromethyl)phenyl]morpholine

4-tert-butyl-2-[3-(trifluoromethyl)phenyl]morpholine

C15H20F3NO (287.14969060000004)


   

2-dodecoxybenzonitrile

2-dodecoxybenzonitrile

C19H29NO (287.2249024)


   

4-(pyrrolidin-1-ylmethyl)benzeneboronic acid, pinacol ester

4-(pyrrolidin-1-ylmethyl)benzeneboronic acid, pinacol ester

C17H26BNO2 (287.2056486)


   

N-(2,4-Dimthylphenyl)-N-p-tolylbenzenamine

N-(2,4-Dimthylphenyl)-N-p-tolylbenzenamine

C21H21N (287.16739060000003)


   

N-(9-phenyl-1-oxaspiro[5.5]undecan-4-yl)acetamide

N-(9-phenyl-1-oxaspiro[5.5]undecan-4-yl)acetamide

C18H25NO2 (287.188519)


   

2-(2-METHYL-2H-TETRAZOL-5-YL)-5-(4,4,5,5-TETRAMETHYL-1,3, - 2DIOXABOROLAN-2-YL)PYRIDINE

2-(2-METHYL-2H-TETRAZOL-5-YL)-5-(4,4,5,5-TETRAMETHYL-1,3, - 2DIOXABOROLAN-2-YL)PYRIDINE

C13H18BN5O2 (287.1553478)


   

2,6-dimethoxy-4-[(1-phenylethylamino)methyl]phenol

2,6-dimethoxy-4-[(1-phenylethylamino)methyl]phenol

C17H21NO3 (287.1521356)


   

tert-butyl 7-ethoxynaphthalen-1-ylcarbamate

tert-butyl 7-ethoxynaphthalen-1-ylcarbamate

C17H21NO3 (287.1521356)


   

tert-Butyl 2,3-dihydrospiro[indene-1,4-piperidine]-1-carboxylate

tert-Butyl 2,3-dihydrospiro[indene-1,4-piperidine]-1-carboxylate

C18H25NO2 (287.188519)


   

tert-Butyl 3-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-1-carboxylate

tert-Butyl 3-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-1-carboxylate

C14H25NO5 (287.173264)


   

4,4-(2-Ethyl-2-nitrotrimethylene)dimorpholine

4,4-(2-ethyl-2-nitropropane-1,3-diyl)bismorpholine

C13H25N3O4 (287.184497)


   

1,3-Dioxolane-4-methanol,2-methyl-2-nonyl-, 4-carbamate

1,3-Dioxolane-4-methanol,2-methyl-2-nonyl-, 4-carbamate

C15H29NO4 (287.2096474)


   

N-BOC-2-OCTYL-L-GLYCINE

N-BOC-2-OCTYL-L-GLYCINE

C15H29NO4 (287.2096474)


   

(2R,3R)-BOC-dolaproine

(2R,3R)-BOC-dolaproine

C14H25NO5 (287.173264)


   

(R)-BoroVal-(+)-Pinanediol-HCl

(R)-BoroVal-(+)-Pinanediol-HCl

C14H27BClNO2 (287.1823262)


   

1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine

1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine

C17H26BNO2 (287.2056486)


   

n,o-bis(tert-butyldimethylsilyl)acetamide

n,o-bis(tert-butyldimethylsilyl)acetamide

C14H33NOSi2 (287.21005679999996)


   
   

2-(DI-TERT-BUTYLPHOSPHINO)-1-PHENYL-1H-PYRROLE

2-(DI-TERT-BUTYLPHOSPHINO)-1-PHENYL-1H-PYRROLE

C18H26NP (287.1802766)


   

BENZYL-(3,4,5-TRIMETHOXYBENZYL)AMINE

BENZYL-(3,4,5-TRIMETHOXYBENZYL)AMINE

C17H21NO3 (287.1521356)


   

1-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)PIPERIDINE

1-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)PIPERIDINE

C17H26BNO2 (287.2056486)


   

(3S,4R)-4-Acetoxy-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one

(3S,4R)-4-Acetoxy-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one

C13H25NO4Si (287.155277)


   

3-Amino-1-(2-ethoxyphenoxy)-1-phenyl-2-propanol

3-Amino-1-(2-ethoxyphenoxy)-1-phenyl-2-propanol

C17H21NO3 (287.1521356)


   

N-Cyclohexyl-4-[(piperidin-1-yl)methyl]benzene-1,2-diamine

N-Cyclohexyl-4-[(piperidin-1-yl)methyl]benzene-1,2-diamine

C18H29N3 (287.2361354)


   

(2-Ethyl-6-methylphenyl)diphenylamine

(2-Ethyl-6-methylphenyl)diphenylamine

C21H21N (287.16739060000003)


   

1-[BIS-(4-FLUOROPHENYL)-METHYL]-PIPERIDINE

1-[BIS-(4-FLUOROPHENYL)-METHYL]-PIPERIDINE

C18H19F2N (287.1485478)


   

1-BOC-4-ETHOXYCARBONYLMETHOXYPIPERIDINE

1-BOC-4-ETHOXYCARBONYLMETHOXYPIPERIDINE

C14H25NO5 (287.173264)


   

(2R,3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol hydrochloride

(2R,3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol hydrochloride

C15H26ClNO2 (287.1651966)


   

Zolmitriptan R-Isomer

Zolmitriptan R-Isomer

C16H21N3O2 (287.1633686)


   

4-AMINO-CHROMAN-8-CARBONITRILEHYDROCHLORIDE

4-AMINO-CHROMAN-8-CARBONITRILEHYDROCHLORIDE

C14H25NO5 (287.173264)


   

1-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)PYRROLIDINE

1-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)PYRROLIDINE

C17H26BNO2 (287.2056486)


   

1-Piperidinecarboxylic acid, 4-(aminoiminomethyl)-, 1,1-dimethylethyl ester, acetate (1:1)

1-Piperidinecarboxylic acid, 4-(aminoiminomethyl)-, 1,1-dimethylethyl ester, acetate (1:1)

C13H25N3O4 (287.184497)


   

N-Cyclopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

N-Cyclopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

C16H22BNO3 (287.16926520000004)


   

(S)-(-)-1,1-DIPHENYL-1,2-PROPANEDIOL

(S)-(-)-1,1-DIPHENYL-1,2-PROPANEDIOL

C21H21N (287.16739060000003)


   

BENZYL-(1-BIPHENYL-4-YL-ETHYL)AMINE

BENZYL-(1-BIPHENYL-4-YL-ETHYL)AMINE

C21H21N (287.16739060000003)


   
   

Moxazocine

Moxazocine

C18H25NO2 (287.188519)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

   
   

4-((4-ethylpiperazin-1-yl)Methyl)-3-(trifluoromethyl)aniline

4-((4-ethylpiperazin-1-yl)Methyl)-3-(trifluoromethyl)aniline

C14H20F3N3 (287.16092360000005)


   

N-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

N-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

C16H22BNO3 (287.16926520000004)


   

Allylprodine

Allylprodine

C18H25NO2 (287.188519)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

   
   

1-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)PYRROLIDINE

1-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)PYRROLIDINE

C17H26BNO2 (287.2056486)


   

tert-butyl 4-(2-ethoxy-2-oxoethyl)-4-hydroxypiperidine-1-carboxylate

tert-butyl 4-(2-ethoxy-2-oxoethyl)-4-hydroxypiperidine-1-carboxylate

C14H25NO5 (287.173264)


   

(R,S)-A-N-BOC-AMINO-B-HYDROXY-CYCLOHEXANEPROPANIC ACID

(R,S)-A-N-BOC-AMINO-B-HYDROXY-CYCLOHEXANEPROPANIC ACID

C14H25NO5 (287.173264)


   

(1S,3R,4R)-3-(Boc-aMino)-4-hydroxy-cyclohexanecarboxylic acid ethyl ester

(1S,3R,4R)-3-(Boc-aMino)-4-hydroxy-cyclohexanecarboxylic acid ethyl ester

C14H25NO5 (287.173264)


   
   

N-formylpropranolol

N-formylpropranolol

C17H21NO3 (287.1521356)


   

Tofacitinib Impurity E

Tofacitinib Impurity E

C15H21N5O (287.1746016)


   

1,1-DIMETHYLETHYL [2-HYDROXY-2-(1-NAPHTHALENYL)ETHYL]CARBAMATE

1,1-DIMETHYLETHYL [2-HYDROXY-2-(1-NAPHTHALENYL)ETHYL]CARBAMATE

C17H21NO3 (287.1521356)


   

triplal / ethyl anthranilate schiffs base

triplal / ethyl anthranilate schiffs base

C18H25NO2 (287.188519)


   

(2S,3R)-1-(dimethylamino)-3-(3-methoxyphenyl)-2-methylpentan-3-ol (hydrochloride)

(2S,3R)-1-(dimethylamino)-3-(3-methoxyphenyl)-2-methylpentan-3-ol (hydrochloride)

C15H26ClNO2 (287.1651966)


   

2-(2,6-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile

2-(2,6-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile

C16H22BNO3 (287.16926520000004)


   

5-Methoxy-1-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole

5-Methoxy-1-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole

C16H22BNO3 (287.16926520000004)


   

Lithium triisopropyl 2-(6-methylpyridyl)borate

Lithium triisopropyl 2-(6-methylpyridyl)borate

C15H27BLiNO3 (287.2243932)


   

Lithium triisopropyl 2-(5-methylpyridyl)borate

Lithium triisopropyl 2-(5-methylpyridyl)borate

C15H27BLiNO3 (287.2243932)


   

N-tert-butyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanimine

N-tert-butyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanimine

C17H26BNO2 (287.2056486)


   

tert-butyl 4-(2-cyanophenyl)piperazine-1-carboxylate

tert-butyl 4-(2-cyanophenyl)piperazine-1-carboxylate

C16H21N3O2 (287.1633686)


   

1,3-Diazaspiro[4.5]decane-2,4-dione,8-methyl-3-[(phenylamino)methyl]-

1,3-Diazaspiro[4.5]decane-2,4-dione,8-methyl-3-[(phenylamino)methyl]-

C16H21N3O2 (287.1633686)


   

citronellal / methyl anthranilate schiffs base

citronellal / methyl anthranilate schiffs base

C18H25NO2 (287.188519)


   

4,4,4-Trimethyltriphenylamine

4,4,4-Trimethyltriphenylamine

C21H21N (287.16739060000003)


   

proxazole

proxazole

C17H25N3O (287.199752)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

Numidargistat

Numidargistat

C11H22BN3O5 (287.1652432)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C308 - Immunotherapeutic Agent D004791 - Enzyme Inhibitors

   

alpha-Pyrrolidinononanophenone

alpha-Pyrrolidinononanophenone

C19H29NO (287.2249024)


   

2-Oxazolidinone, 4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-

2-Oxazolidinone, 4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-

C16H21N3O2 (287.1633686)


   
   
   
   

(R)-trichostatic acid

(R)-trichostatic acid

C17H21NO3 (287.1521356)


   
   

Plasmocid

Plasmocid

C17H25N3O (287.199752)


D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents

   

(S)-trichostatic acid

(S)-trichostatic acid

C17H21NO3 (287.1521356)


   
   

O-octanoyl-D-carnitine

O-octanoyl-D-carnitine

C15H29NO4 (287.2096474)


An O-acyl-D-carnitine in which the acyl group specified as octanoyl.

   

2-Aminoestra-1,3,5(10)-triene-3,17beta-diol

2-Aminoestra-1,3,5(10)-triene-3,17beta-diol

C18H25NO2 (287.188519)


   

4-Aminoestra-1,3,5(10)-triene-3,17beta-diol

4-Aminoestra-1,3,5(10)-triene-3,17beta-diol

C18H25NO2 (287.188519)


   

N4-(4-methoxyphenyl)-1,3,5-triazaspiro[5.5]undeca-1,4-diene-2,4-diamine

N4-(4-methoxyphenyl)-1,3,5-triazaspiro[5.5]undeca-1,4-diene-2,4-diamine

C15H21N5O (287.1746016)


   
   

3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-methylpropanamide

3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-methylpropanamide

C16H21N3O2 (287.1633686)


   
   

L-Valyl-L-leucylglycine

L-Valyl-L-leucylglycine

C13H25N3O4 (287.184497)


   

Glycyl-L-isoleucyl-L-valine

Glycyl-L-isoleucyl-L-valine

C13H25N3O4 (287.184497)


   

1-Octyl-2,8,9-trioxa-5-aza-1-silabicyclo[3.3.3]undecane

1-Octyl-2,8,9-trioxa-5-aza-1-silabicyclo[3.3.3]undecane

C14H29NO3Si (287.1916604)


   

3,4-Dibenzyl-2,5-dimethylpyridine

3,4-Dibenzyl-2,5-dimethylpyridine

C21H21N (287.16739060000003)


   

(1s,2s,3r,6r)-4-(Hydroxymethyl)-6-(Octylamino)cyclohex-4-Ene-1,2,3-Triol

(1s,2s,3r,6r)-4-(Hydroxymethyl)-6-(Octylamino)cyclohex-4-Ene-1,2,3-Triol

C15H29NO4 (287.2096474)


   

4-{[(2s)-3-(Tert-Butylamino)-2-Hydroxypropyl]oxy}-3h-Indole-2-Carbonitrile

4-{[(2s)-3-(Tert-Butylamino)-2-Hydroxypropyl]oxy}-3h-Indole-2-Carbonitrile

C16H21N3O2 (287.1633686)


   

(1S)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol

(1S)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol

C17H21NO3 (287.1521356)


   

10,16-Dihydroxyhexadecanoate

10,16-Dihydroxyhexadecanoate

C16H31O4- (287.2222226)


   

9,16-Dihydroxyhexadecanoate

9,16-Dihydroxyhexadecanoate

C16H31O4- (287.2222226)


   

3-oxononanoyl-N-acetylcysteamine

3-oxononanoyl-N-acetylcysteamine

C14H25NO3S (287.155506)


   

[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-oxo-2-phenylpropanoate

[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-oxo-2-phenylpropanoate

C17H21NO3 (287.1521356)


   

Nordihydroisomorphine

Nordihydroisomorphine

C17H21NO3 (287.1521356)


   
   

3-Oxoheptanoylcarnitine

3-Oxoheptanoylcarnitine

C14H25NO5 (287.173264)


   

3-Methylheptanoylcarnitine

3-Methylheptanoylcarnitine

C15H29NO4 (287.2096474)


   

4-Methylheptanoylcarnitine

4-Methylheptanoylcarnitine

C15H29NO4 (287.2096474)


   

6-Methylheptanoylcarnitine

6-Methylheptanoylcarnitine

C15H29NO4 (287.2096474)


   

5-Methylheptanoylcarnitine

5-Methylheptanoylcarnitine

C15H29NO4 (287.2096474)


   

2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-ylmethyl (E)-3-(4-hydroxyphenyl)prop-2-enoate

2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-ylmethyl (E)-3-(4-hydroxyphenyl)prop-2-enoate

C17H21NO3 (287.1521356)


   

3-Hydroxyhept-4-enoylcarnitine

3-Hydroxyhept-4-enoylcarnitine

C14H25NO5 (287.173264)


   

2-Hydroxyhept-5-enoylcarnitine

2-Hydroxyhept-5-enoylcarnitine

C14H25NO5 (287.173264)


   

(5E)-3-Hydroxyhept-5-enoylcarnitine

(5E)-3-Hydroxyhept-5-enoylcarnitine

C14H25NO5 (287.173264)


   

Yutopar

4-[2-[[(1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol

C17H21NO3 (287.1521356)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents

   

4-[(Bicyclo[4.1.0]heptane-7-carbonyl)-amino]-benzoic acid ethyl ester

4-[(Bicyclo[4.1.0]heptane-7-carbonyl)-amino]-benzoic acid ethyl ester

C17H21NO3 (287.1521356)


   

(2E)-3-azepan-1-yl-2-[(3-fluorophenyl)hydrazono]-3-iminopropanenitrile

(2E)-3-azepan-1-yl-2-[(3-fluorophenyl)hydrazono]-3-iminopropanenitrile

C15H18FN5 (287.15461600000003)


   

N-Acetyl-ala-ala-ala-methylester

N-Acetyl-ala-ala-ala-methylester

C12H21N3O5 (287.1481136)


   

Isoleucyl-Arginine

Isoleucyl-Arginine

C12H25N5O3 (287.19573)


   
   

3,4-Quinolinediol, 2-nonyl-

3,4-Quinolinediol, 2-nonyl-

C18H25NO2 (287.188519)


   

3,16-Dihydroxypalmitate

3,16-Dihydroxypalmitate

C16H31O4- (287.2222226)


A hydroxy fatty acid anion that is the conjugate base of 3,16-dihydroxypalmitic acid, arising from deprotonation of the carboxy group; major species at pH 7.3.

   

4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile

4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile

C16H21N3O2 (287.1633686)


   

Leu-Val-Gly

Leu-Val-Gly

C13H25N3O4 (287.184497)


A tripeptide composed of L-leucine, L-valine and glycine joined in sequence by peptide linkages.

   

(2S,3R)-2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid

(2S,3R)-2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid

C12H21N3O5 (287.1481136)


   

1-[(3-hydroxy-4-methoxyphenyl)methyl]-2,3,4,7,8,8a-hexahydro-1H-isoquinolin-6-one

1-[(3-hydroxy-4-methoxyphenyl)methyl]-2,3,4,7,8,8a-hexahydro-1H-isoquinolin-6-one

C17H21NO3 (287.1521356)


   

3-[5-(4-Methoxyphenyl)-1-propyl-2-pyrrolyl]propanoic acid

3-[5-(4-Methoxyphenyl)-1-propyl-2-pyrrolyl]propanoic acid

C17H21NO3 (287.1521356)


   

N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propionamide

N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propionamide

C17H21NO3 (287.1521356)


   

N-[(2R)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propionamide

N-[(2R)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propionamide

C17H21NO3 (287.1521356)


   

N-[3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propionamide

N-[3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propionamide

C17H21NO3 (287.1521356)


   

(4aR,7aR)-9-methoxy-3-methyl-2,4,4a,5,6,7a-hexahydro-1H-benzofuro[3,2-e]isoquinolin-7-one

(4aR,7aR)-9-methoxy-3-methyl-2,4,4a,5,6,7a-hexahydro-1H-benzofuro[3,2-e]isoquinolin-7-one

C17H21NO3 (287.1521356)


   

(2R)-2-hydroperoxyhexadecanoate

(2R)-2-hydroperoxyhexadecanoate

C16H31O4- (287.2222226)


   

Glycyl-valyl-isoleucine

Glycyl-valyl-isoleucine

C13H25N3O4 (287.184497)


   
   

Glycyl-valyl-leucine

Glycyl-valyl-leucine

C13H25N3O4 (287.184497)


   
   
   
   
   

1-Piperidinyl-[1-(3-pyridinylmethyl)-3-piperidinyl]methanone

1-Piperidinyl-[1-(3-pyridinylmethyl)-3-piperidinyl]methanone

C17H25N3O (287.199752)


   
   

N-ethyl-3-[3-(4-propan-2-ylphenyl)-1,2,4-oxadiazol-5-yl]propanamide

N-ethyl-3-[3-(4-propan-2-ylphenyl)-1,2,4-oxadiazol-5-yl]propanamide

C16H21N3O2 (287.1633686)


   

N-[(E)-1-(4-acetamidophenyl)ethylideneamino]cyclopentanecarboxamide

N-[(E)-1-(4-acetamidophenyl)ethylideneamino]cyclopentanecarboxamide

C16H21N3O2 (287.1633686)


   

(3R,8Z,11R)-11-methyl-3-phenyl-1-oxa-5-azacyclododec-8-ene-4,12-dione

(3R,8Z,11R)-11-methyl-3-phenyl-1-oxa-5-azacyclododec-8-ene-4,12-dione

C17H21NO3 (287.1521356)


   

ethyl 2-[(1S)-8-ethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetate

ethyl 2-[(1S)-8-ethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetate

C17H21NO3 (287.1521356)


   

(4S,9Z,12R)-12-methyl-4-phenyl-1-oxa-5-azacyclododec-9-ene-2,6-dione

(4S,9Z,12R)-12-methyl-4-phenyl-1-oxa-5-azacyclododec-9-ene-2,6-dione

C17H21NO3 (287.1521356)


   
   
   
   
   
   
   
   
   
   

9,14-Dihydroxyhexadecanoate

9,14-Dihydroxyhexadecanoate

C16H31O4- (287.2222226)


   

9,15-Dihydroxyhexadecanoate

9,15-Dihydroxyhexadecanoate

C16H31O4- (287.2222226)


   

9,13-Dihydroxyhexadecanoate

9,13-Dihydroxyhexadecanoate

C16H31O4- (287.2222226)


   

(2E)-8-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]oct-2-enoate

(2E)-8-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]oct-2-enoate

C14H23O6- (287.1494558)


   

2-(1,8-diethyl-4,8-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid

2-(1,8-diethyl-4,8-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid

C17H21NO3 (287.1521356)


   

2-[(4-Methoxyphenyl)methyliminomethyl]-5,5-dimethylcyclohexane-1,3-dione

2-[(4-Methoxyphenyl)methyliminomethyl]-5,5-dimethylcyclohexane-1,3-dione

C17H21NO3 (287.1521356)


   

Octanoyl-L-carnitine-(N-methyl-d3), analytical standard

Octanoyl-L-carnitine-(N-methyl-d3), analytical standard

C15H29NO4 (287.2096474)


   

(E,7R)-7-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyoct-2-enoate

(E,7R)-7-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyoct-2-enoate

C14H23O6- (287.1494558)


   

[4-Methyl-1-(1-methylindol-3-yl)-3-oxopentan-2-yl] acetate

[4-Methyl-1-(1-methylindol-3-yl)-3-oxopentan-2-yl] acetate

C17H21NO3 (287.1521356)


   

4-[3-(4-Acetamidobutylamino)propylamino]-4-oxobutanoic acid

4-[3-(4-Acetamidobutylamino)propylamino]-4-oxobutanoic acid

C13H25N3O4 (287.184497)


   

[(2S,4S)-1-(1H-indol-3-yl)-4-methyl-3-oxohexan-2-yl] acetate

[(2S,4S)-1-(1H-indol-3-yl)-4-methyl-3-oxohexan-2-yl] acetate

C17H21NO3 (287.1521356)


   

[(2S)-1-(1H-indol-3-yl)-4-methyl-3-oxopentan-2-yl] propanoate

[(2S)-1-(1H-indol-3-yl)-4-methyl-3-oxopentan-2-yl] propanoate

C17H21NO3 (287.1521356)


   

4-[4-(3-Acetamidopropylamino)butylamino]-4-oxobutanoic acid

4-[4-(3-Acetamidopropylamino)butylamino]-4-oxobutanoic acid

C13H25N3O4 (287.184497)


   

2,4-Dibenzyl-3,6-dimethylpyridine

2,4-Dibenzyl-3,6-dimethylpyridine

C21H21N (287.16739060000003)


   

N-Acetyl-glycyl-valyl-glycine methylester

N-Acetyl-glycyl-valyl-glycine methylester

C12H21N3O5 (287.1481136)


   

N-Acetyl-alanyl-alanyl-alanine methyl ester

N-Acetyl-alanyl-alanyl-alanine methyl ester

C12H21N3O5 (287.1481136)


   

procyclidine

1-Pyrrolidinepropanol, a-cyclohexyl-a-phenyl-

C19H29NO (287.2249024)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

ritodrine

ritodrine

C17H21NO3 (287.1521356)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents

   

Dihydromorphine

Dihydromorphine

C17H21NO3 (287.1521356)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Epigalanthamin

Epigalanthamin

C17H21NO3 (287.1521356)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010277 - Parasympathomimetics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D002491 - Central Nervous System Agents > D018697 - Nootropic Agents D004791 - Enzyme Inhibitors

   

Ritodrina

Ritodrine hydrochloride

C17H21NO3 (287.1521356)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents

   

Cyanopindolol

Cyanopindolol

C16H21N3O2 (287.1633686)


D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists

   
   
   

arginylisoleucine

arginylisoleucine

C12H25N5O3 (287.19573)


   
   

6alpha-Hydroxy-hydromorphone

6alpha-Hydroxy-hydromorphone

C17H21NO3 (287.1521356)


   

O-octanoylcarnitine

O-octanoylcarnitine

C15H29NO4 (287.2096474)


An O-acylcarnitine having octanoyl as the acyl substituent.

   
   

ascr#13(1-)

ascr#13(1-)

C14H23O6 (287.1494558)


Conjugate base of ascr#13

   
   

oscr#13(1-)

oscr#13(1-)

C14H23O6 (287.1494558)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#13, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

O-octanoyl-L-carnitine

O-octanoyl-L-carnitine

C15H29NO4 (287.2096474)


The L-enantiomer of an O-octanoylcarnitine.

   
   
   
   
   
   
   
   
   
   
   
   
   

O-Desmethyl Mebeverine alcohol (hydrochloride)

O-Desmethyl Mebeverine alcohol (hydrochloride)

C15H26ClNO2 (287.1651966)


O-Desmethyl Mebeverine alcohol hydrochloride is a metabolite of Mebeverine, which is a potent α1 repector inhibitor, causing relaxation of the gastrointestinal tract.

   

3-methyl-1-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-2,3-diol

3-methyl-1-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-2,3-diol

C18H25NO2 (287.188519)


   

n-{3-[(1r)-6-hydroxy-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl]propyl}guanidine

n-{3-[(1r)-6-hydroxy-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl]propyl}guanidine

C15H21N5O (287.1746016)


   

1-(1h-indol-3-yl)-4-methyl-3-oxohexan-2-yl acetate

1-(1h-indol-3-yl)-4-methyl-3-oxohexan-2-yl acetate

C17H21NO3 (287.1521356)


   

11-[(2-oxopyrrolidin-1-yl)methyl]-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,4-dien-6-one

11-[(2-oxopyrrolidin-1-yl)methyl]-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,4-dien-6-one

C16H21N3O2 (287.1633686)


   

2-[(2r,6s)-6-[(2s)-2-hydroxybutyl]-1-methyl-3,6-dihydro-2h-pyridin-2-yl]-1-phenylethanone

2-[(2r,6s)-6-[(2s)-2-hydroxybutyl]-1-methyl-3,6-dihydro-2h-pyridin-2-yl]-1-phenylethanone

C18H25NO2 (287.188519)


   

5-(4-hydroxy-3-methoxyphenyl)-1-(piperidin-1-yl)penta-2,4-dien-1-one

5-(4-hydroxy-3-methoxyphenyl)-1-(piperidin-1-yl)penta-2,4-dien-1-one

C17H21NO3 (287.1521356)


   

(1r,5r)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-phenylprop-2-enoate

(1r,5r)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-phenylprop-2-enoate

C17H21NO3 (287.1521356)


   

6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-phenylprop-2-enoate

6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-phenylprop-2-enoate

C17H21NO3 (287.1521356)


   

(2s,6r,7s,8s)-7-[(1e)-buta-1,3-dien-1-yl]-2-(penta-3,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

(2s,6r,7s,8s)-7-[(1e)-buta-1,3-dien-1-yl]-2-(penta-3,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

C19H29NO (287.2249024)


   

(9bs,11r,12r)-11-methoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-8,12-diol

(9bs,11r,12r)-11-methoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-8,12-diol

C17H21NO3 (287.1521356)


   

1-[(1s,4s,10s,12r)-9-[(1e)-but-1-en-1-yl]-6-imino-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8-en-5-yl]ethanone

1-[(1s,4s,10s,12r)-9-[(1e)-but-1-en-1-yl]-6-imino-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8-en-5-yl]ethanone

C17H25N3O (287.199752)


   

2-epigalanthamine

NA

C17H21NO3 (287.1521356)


{"Ingredient_id": "HBIN005583","Ingredient_name": "2-epigalanthamine","Alias": "NA","Ingredient_formula": "C17H21NO3","Ingredient_Smile": "CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6919","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1s,3r,5s,6r)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (2e)-3-phenylprop-2-enoate

(1s,3r,5s,6r)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (2e)-3-phenylprop-2-enoate

C17H21NO3 (287.1521356)


   

4,8-dimethoxy-1-methyl-3-(3-methylbut-2-en-1-yl)quinolin-2-one

4,8-dimethoxy-1-methyl-3-(3-methylbut-2-en-1-yl)quinolin-2-one

C17H21NO3 (287.1521356)


   

n-(3-{6-hydroxy-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl}propyl)guanidine

n-(3-{6-hydroxy-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl}propyl)guanidine

C15H21N5O (287.1746016)


   

3a-(3,4-dimethoxyphenyl)-1-methyl-2,3,7,7a-tetrahydroindol-6-one

3a-(3,4-dimethoxyphenyl)-1-methyl-2,3,7,7a-tetrahydroindol-6-one

C17H21NO3 (287.1521356)


   

2-[6-(2-hydroxybutyl)-1-methyl-3,6-dihydro-2h-pyridin-2-yl]-1-phenylethanone

2-[6-(2-hydroxybutyl)-1-methyl-3,6-dihydro-2h-pyridin-2-yl]-1-phenylethanone

C18H25NO2 (287.188519)


   

(2r)-3-methyl-2-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-1,3-diol

(2r)-3-methyl-2-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-1,3-diol

C18H25NO2 (287.188519)


   

1-hydroxy-2-nonylquinolin-4-one

1-hydroxy-2-nonylquinolin-4-one

C18H25NO2 (287.188519)


   

(2r)-1-(1h-indol-3-yl)-4-methyl-3-oxohexan-2-yl acetate

(2r)-1-(1h-indol-3-yl)-4-methyl-3-oxohexan-2-yl acetate

C17H21NO3 (287.1521356)


   

(1r,9s)-11-[(2-oxopyrrolidin-1-yl)methyl]-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,4-dien-6-one

(1r,9s)-11-[(2-oxopyrrolidin-1-yl)methyl]-7,11-diazatricyclo[7.3.1.0²,⁷]trideca-2,4-dien-6-one

C16H21N3O2 (287.1633686)


   

6-[(1r,2s,4ar,8ar)-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-4-amino-2-oxopyran-3-carbaldehyde

6-[(1r,2s,4ar,8ar)-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-4-amino-2-oxopyran-3-carbaldehyde

C17H21NO3 (287.1521356)


   

2-(9-hydroxynonyl)-1h-quinolin-4-one

2-(9-hydroxynonyl)-1h-quinolin-4-one

C18H25NO2 (287.188519)


   

2-methyl-n-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidic acid

2-methyl-n-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidic acid

C18H25NO2 (287.188519)


   

(1s,12s,14r)-14-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraen-9-ol

(1s,12s,14r)-14-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraen-9-ol

C17H21NO3 (287.1521356)


   

5-(2h-1,3-benzodioxol-5-yl)-n-(2-methylbutyl)penta-2,4-dienamide

5-(2h-1,3-benzodioxol-5-yl)-n-(2-methylbutyl)penta-2,4-dienamide

C17H21NO3 (287.1521356)


   

(3as)-3a-(3,4-dimethoxyphenyl)-1-methyl-2,3,7,7a-tetrahydroindol-6-one

(3as)-3a-(3,4-dimethoxyphenyl)-1-methyl-2,3,7,7a-tetrahydroindol-6-one

C17H21NO3 (287.1521356)


   

9-methyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-7-yl 2-phenylpropanoate

9-methyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-7-yl 2-phenylpropanoate

C17H21NO3 (287.1521356)


   

(10s,13s)-13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

(10s,13s)-13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C16H21N3O2 (287.1633686)


   

6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-phenylprop-2-enoate

6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-phenylprop-2-enoate

C17H21NO3 (287.1521356)


   

(2s,6r,7s,8s)-7-(buta-1,3-dien-1-yl)-2-(penta-3,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

(2s,6r,7s,8s)-7-(buta-1,3-dien-1-yl)-2-(penta-3,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

C19H29NO (287.2249024)


   

(1r,10s,12r)-4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-12-ol

(1r,10s,12r)-4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-12-ol

C17H21NO3 (287.1521356)


   

(1r,10s,12s)-4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-12-ol

(1r,10s,12s)-4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-12-ol

C17H21NO3 (287.1521356)


   

(2e,4e)-5-(2h-1,3-benzodioxol-5-yl)-n-(3-methylbutyl)penta-2,4-dienimidic acid

(2e,4e)-5-(2h-1,3-benzodioxol-5-yl)-n-(3-methylbutyl)penta-2,4-dienimidic acid

C17H21NO3 (287.1521356)


   

13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C16H21N3O2 (287.1633686)


   

(2e)-2-methyl-n-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidic acid

(2e)-2-methyl-n-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidic acid

C18H25NO2 (287.188519)


   

(2s,6r,7s,8s)-7-[(1e)-buta-1,3-dien-1-yl]-2-[(2e)-penta-2,4-dien-1-yl]-1-azaspiro[5.5]undecan-8-ol

(2s,6r,7s,8s)-7-[(1e)-buta-1,3-dien-1-yl]-2-[(2e)-penta-2,4-dien-1-yl]-1-azaspiro[5.5]undecan-8-ol

C19H29NO (287.2249024)


   

(2s)-3-methyl-1-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-2,3-diol

(2s)-3-methyl-1-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-2,3-diol

C18H25NO2 (287.188519)


   

14-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraen-9-ol

14-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraen-9-ol

C17H21NO3 (287.1521356)


   

(+)-trichostatic acid

(+)-trichostatic acid

C17H21NO3 (287.1521356)


   

(1s,15r,16s)-4,5-dimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

(1s,15r,16s)-4,5-dimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

C17H21NO3 (287.1521356)


   

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,2-dimethylpropanamide

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,2-dimethylpropanamide

C18H25NO2 (287.188519)


   

n-[(1s,9s,10r)-9-butyl-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid

n-[(1s,9s,10r)-9-butyl-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid

C17H25N3O (287.199752)


   

5-(2h-1,3-benzodioxol-5-yl)-n-(3-methylbutyl)penta-2,4-dienamide

5-(2h-1,3-benzodioxol-5-yl)-n-(3-methylbutyl)penta-2,4-dienamide

C17H21NO3 (287.1521356)


   

(1s,4s,12'r)-3',5'-dioxa-11'-azaspiro[cyclohexane-1,14'-tetracyclo[6.6.1.0²,⁶.0¹²,¹⁵]pentadecane]-1'(15'),2'(6'),7'-trien-4-ol

(1s,4s,12'r)-3',5'-dioxa-11'-azaspiro[cyclohexane-1,14'-tetracyclo[6.6.1.0²,⁶.0¹²,¹⁵]pentadecane]-1'(15'),2'(6'),7'-trien-4-ol

C17H21NO3 (287.1521356)


   

(1s,15r)-4,5-dimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

(1s,15r)-4,5-dimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

C17H21NO3 (287.1521356)


   

4-(2-{[(3,4-dimethoxyphenyl)methyl]amino}ethyl)phenol

4-(2-{[(3,4-dimethoxyphenyl)methyl]amino}ethyl)phenol

C17H21NO3 (287.1521356)


   

5-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)pent-2-en-1-one

5-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)pent-2-en-1-one

C17H21NO3 (287.1521356)


   

(2s,6r,7s,8s)-7-(buta-1,3-dien-1-yl)-2-(penta-2,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

(2s,6r,7s,8s)-7-(buta-1,3-dien-1-yl)-2-(penta-2,4-dien-1-yl)-1-azaspiro[5.5]undecan-8-ol

C19H29NO (287.2249024)


   

n-[2-(4-hydroxyphenyl)ethyl]deca-2,4-dienimidic acid

n-[2-(4-hydroxyphenyl)ethyl]deca-2,4-dienimidic acid

C18H25NO2 (287.188519)


   

(2e,4e,8z,11z)-1-(piperidin-1-yl)tetradeca-2,4,8,11-tetraen-1-one

(2e,4e,8z,11z)-1-(piperidin-1-yl)tetradeca-2,4,8,11-tetraen-1-one

C19H29NO (287.2249024)


   

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-3-methylbutanimidic acid

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-3-methylbutanimidic acid

C18H25NO2 (287.188519)


   

4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-12-ol

4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-12-ol

C17H21NO3 (287.1521356)


   

(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-5-carbamimidamidopentanoic acid

(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-5-carbamimidamidopentanoic acid

C12H25N5O3 (287.19573)


   

3-methyl-2-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-1,3-diol

3-methyl-2-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-1,3-diol

C18H25NO2 (287.188519)


   

3-methyl-1-[3-(2-methylbut-3-en-2-yl)-1h-indol-7-yl]butane-2,3-diol

3-methyl-1-[3-(2-methylbut-3-en-2-yl)-1h-indol-7-yl]butane-2,3-diol

C18H25NO2 (287.188519)


   

2-heptyl-8-methoxy-1-methylquinolin-4-one

2-heptyl-8-methoxy-1-methylquinolin-4-one

C18H25NO2 (287.188519)


   

n-{9-butyl-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl}ethanimidic acid

n-{9-butyl-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl}ethanimidic acid

C17H25N3O (287.199752)


   

1-[9-(but-1-en-1-yl)-6-imino-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8-en-5-yl]ethanone

1-[9-(but-1-en-1-yl)-6-imino-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8-en-5-yl]ethanone

C17H25N3O (287.199752)


   

3',5'-dioxa-11'-azaspiro[cyclohexane-1,14'-tetracyclo[6.6.1.0²,⁶.0¹²,¹⁵]pentadecane]-1'(15'),2'(6'),7'-trien-4-ol

3',5'-dioxa-11'-azaspiro[cyclohexane-1,14'-tetracyclo[6.6.1.0²,⁶.0¹²,¹⁵]pentadecane]-1'(15'),2'(6'),7'-trien-4-ol

C17H21NO3 (287.1521356)


   

15-methoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-triene

15-methoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-triene

C17H21NO3 (287.1521356)


   

(2e,4e)-5-(4-hydroxy-3-methoxyphenyl)-1-(piperidin-1-yl)penta-2,4-dien-1-one

(2e,4e)-5-(4-hydroxy-3-methoxyphenyl)-1-(piperidin-1-yl)penta-2,4-dien-1-one

C17H21NO3 (287.1521356)


   

2-{[(2e,4e)-1-hydroxy-4-methylhexa-2,4-dien-1-ylidene]amino}-3-phenylbutanoic acid

2-{[(2e,4e)-1-hydroxy-4-methylhexa-2,4-dien-1-ylidene]amino}-3-phenylbutanoic acid

C17H21NO3 (287.1521356)


   

(1r,12s)-5,12-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-4-ol

(1r,12s)-5,12-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-4-ol

C17H21NO3 (287.1521356)


   

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]deca-2,4-dienimidic acid

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]deca-2,4-dienimidic acid

C18H25NO2 (287.188519)


   

(2e,4e)-5-(2h-1,3-benzodioxol-5-yl)-n-[(2r)-2-methylbutyl]penta-2,4-dienimidic acid

(2e,4e)-5-(2h-1,3-benzodioxol-5-yl)-n-[(2r)-2-methylbutyl]penta-2,4-dienimidic acid

C17H21NO3 (287.1521356)